NCT04233294 2020-08-14
Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown
Clinical Trials
4 trialsNCT04510610 2020-08-12
Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2/3 Unknown
NCT04239170 2020-01-23
Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma
Peking University
Phase 2 Unknown
NCT03250962 2019-04-01
SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 2 Unknown